Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent developments in macrolide antimicrobial research.

Toshifumi Asaka1, Akira Manaka, Hiroyuki Sugiyama

  • 1Medicinal Research Laboratories, Taisho Pharmaceutical Co, Ltd, 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan. toshifumi.asaka@po.rd.taisho.co.jp

Current Topics in Medicinal Chemistry
|April 8, 2003
PubMed
Summary

New macrolide antibiotics are being developed to combat drug resistance in respiratory tract infections. Modified macrolides show promise against resistant bacteria, addressing limitations of current treatments like clarithromycin and azithromycin.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Current and novel dual orexin receptor antagonists for the treatment of insomnia: the emergence of vornorexant.

The international journal of neuropsychopharmacology·2025
Same author

TP0586532, a Novel Non-Hydroxamate LpxC Inhibitor: Potentiating Effect on <i>In Vitro</i> Activity of Meropenem against Carbapenem-Resistant Enterobacteriaceae.

Microbiology spectrum·2022
Same author

Pharmacodynamic target assessment and prediction of clinically effective dosing regimen of TP0586532, a novel non-hydroxamate LpxC inhibitor, using a murine lung infection model.

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy·2022
Same author

TP0586532, a non-hydroxamate LpxC inhibitor, reduces LPS release and IL-6 production both in vitro and in vivo.

The Journal of antibiotics·2022
Same author

[Preface].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2022
Same author

[COVID-19 drug candidate pipeline, an overview].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2022

Area of Science:

  • Medicinal Chemistry
  • Microbiology
  • Pharmacology

Background:

  • Clarithromycin and azithromycin are effective against respiratory tract infections but struggle against bacteria with specific resistance genes (mef, erm).
  • Existing macrolide antibiotics face challenges with acid stability and activity against resistant bacterial strains.

Purpose of the Study:

  • To review advancements in macrolide antibiotic research.
  • To discuss the development of next-generation macrolides to overcome drug resistance.

Main Methods:

  • Review of scientific literature on macrolide antibiotic modifications.
  • Analysis of novel macrolide derivatives, including ketolides, acylides, and aryl-substituted compounds.

Main Results:

Related Experiment Videos

  • Decladinosyl derivatives (ketolides, acylides) show efficacy against mef- and erm-resistant bacteria.
  • Aryl-substituted macrolides like telithromycin and cethromycin are effective against erm(B)-resistant streptococci.
  • Telithromycin is approved in Europe; cethromycin is in late-stage clinical trials.

Conclusions:

  • Macrolide antibiotic modifications are crucial for overcoming bacterial resistance.
  • Next-generation macrolides with improved structural features are needed for future treatments.